113PANLOTINIB AS THIRD-LINE TREATMENT IN PATIENTS WITH REFRACTORY ADVANCED NON-SMALL CELL LUNG CANCER: A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II TRIAL (NCT01924195)
2015
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI